Human Genome Epidemiology Literature Finder
|
Records 1 - 15 (of 15 Records) |
| Query Trace: Pancreatic Neoplasms and UGT1A1[original query] |
|---|
| Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. Cancer chemotherapy and pharmacology 2013 Jan 71 (1): 85-92. Takahara Naminatsu, Nakai Yousuke, Isayama Hiroyuki, Sasaki Takashi, Satoh Yumiko, Takai Daiya, Hamada Tsuyoshi, Uchino Rie, Mizuno Suguru, Miyabayashi Koji, Mohri Dai, Kawakubo Kazumichi, Kogure Hirofumi, Yamamoto Natsuyo, Sasahira Naoki, Hirano Kenji, Ijichi Hideaki, Tada Minoru, Yatomi Yutaka, Koike Kazuhi |
| Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Drug design, development and therapy 2015 9 3677-83. Yang Chen, Liu Ying, Xi Wen-qi, Zhou Chen-fei, Jiang Jin-ling, Ma Tao, Ye Zheng-bao, Zhang Jun, Zhu Zheng-ga |
| [Treating Side Effects of FOLFIRINOX--A Study of the Effect of Hange-Shashin-To on Preventing Diarrhea]. Gan to kagaku ryoho. Cancer & chemotherapy 2015 Nov 42 (12): 2364-6. Hoshi Nobuhiro, Kofunato Yasuhide, Yashima Rei, Shimura Tatsuo, Takenoshita Seiic |
| Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma. Frontiers in pharmacology 2018 9 1309. Velez-Velez Lisa M, Hughes Caren L, Kasi Pashtoon Murta |
| Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Cancer science 2019 Feb 110 (2): 707-716. Shirasu Hiromichi, Todaka Akiko, Omae Katsuhiro, Fujii Hirofumi, Mizuno Nobumasa, Ozaka Masato, Ueno Hideki, Kobayashi Satoshi, Uesugi Kazuhiro, Kobayashi Noritoshi, Hayashi Hideyuki, Sudo Kentaro, Okano Naohiro, Horita Yosuke, Kamei Keiko, Yukisawa Seigo, Kobayashi Marina, Fukutomi Aki |
| A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer 2019 Jan . Sharma Manish R, Joshi Smita S, Karrison Theodore G, Allen Kenisha, Suh Grace, Marsh Robert, Kozloff Mark F, Polite Blase N, Catenacci Daniel V T, Kindler Hedy |
| Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. European journal of drug metabolism and pharmacokinetics 2021 2 46 (2): 317-324. Yokokawa Akitomo, Kaneko Shun, Endo Sayuri, Minowa Yuki, Ayukawa Hideaki, Hirano Ryohei, Nagashima Fumio, Naruge Daisuke, Okano Naohiro, Kobayashi Takaaki, Kawai Kirio, Furuse Junji, Furuta Takashi, Shibasaki Hiro |
| FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Cancer chemotherapy and pharmacology 2021 Jan . Umemoto Kumiko, Takahashi Hideaki, Morizane Chigusa, Yamada Ikuhiro, Shimizu Satoshi, Shioji Kazuhiko, Yoshida Yukio, Motoya Masayo, Mizuno Nobumasa, Kojima Yasushi, Terashima Takeshi, Uesugi Kazuhiro, Ueno Makoto, Furuse Junji, Akimoto Tetsuo, Ikeda Masafu |
| Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. The pharmacogenomics journal 2021 Jan . Vivaldi Caterina, Crucitta Stefania, Catanese Silvia, Cucchiara Federico, Arrigoni Elena, Pecora Irene, Rofi Eleonora, Fornaro Lorenzo, Salani Francesca, Massa Valentina, Vasile Enrico, Morganti Riccardo, Danesi Romano, Del Re Marz |
| Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. Scientific reports 2022 9 12 (1): 15574. Irisawa Ai, Takeno Misaki, Watanabe Kazuo, Takahashi Hideaki, Mitsunaga Shuichi, Ikeda Masafu |
| The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. International journal of clinical oncology 2022 5 27 (8): 1331-1339. Satake Tomoyuki, Morizane Chigusa, Maruki Yuta, Ohba Akihiro, Nagashio Yoshikuni, Kondo Shunsuke, Hijioka Susumu, Ueno Hideki, Okusaka Taku |
| Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Cancers 2022 3 14 (5): . Keum Jiyoung, Lee Hee Seung, Jo Jung Hyun, Chung Moon Jae, Park Jeong Youp, Park Seung Woo, Song Si Young, Bang Seungm |
| Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Cancer medicine 2022 10 . Kanesada Kou, Tsunedomi Ryouichi, Hazama Shoichi, Ogihara Hiroyuki, Hamamoto Yoshihiko, Shindo Yoshitaro, Matsui Hiroto, Tokumitsu Yukio, Yoshida Shin, Iida Michihisa, Suzuki Nobuaki, Takeda Shigeru, Ioka Tatsuya, Nagano Hiroa |
| Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer. Genetic testing and molecular biomarkers 2023 5 27 (5): 133-141. Zineb Aoullay, Andrew Smith, Meriem Slaoui, Ihssane El Bouchikhi, Hassan Ghazal, Najib Al Idrissi, Bouchra Meddah, Kara L Lynch, Yahia Cherrah, Alan H B |
| Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin. Cancer diagnosis & prognosis 2024 5 4 (3): 244-249. Takahiro Ito, Manabu Suno, Hideki Egawa, Serina Hiraoka, Kohei Kamei, Shohei Sano, Reiko Ashida, Manabu Kawai, Kazuo Matsuba |
- Page last reviewed:Feb 1, 2024
- Content source: